Prelude Therapeutics (PRLD) Income towards Parent Company (2019 - 2026)

Prelude Therapeutics has reported Income towards Parent Company for 8 years, with the latest figure at -$34.4 million in Q1 2026.

• Quarterly Income towards Parent Company rose 40.15% year-over-year to -$34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$149.0 million (up 39.97% YoY) and the FY2025 annual result came in at -$316.5 million, up 1.83% from the prior year.
• Income towards Parent Company retreated to -$34.4 million in Q1 2026 per PRLD's latest filing, from -$18.1 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$18.1 million in Q4 2025 and troughed at -$144.4 million in Q4 2022.
• A 5-year average of -$52.4 million and a median of -$41.6 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company jumped 83.64% in 2022, then plunged 112.54% in 2024.
• Over 5 years, Income towards Parent Company stood at -$144.4 million in 2022, then jumped by 73.79% to -$37.9 million in 2023, then gained by 9.24% to -$34.4 million in 2024, then surged by 47.38% to -$18.1 million in 2025, then tumbled by 90.49% to -$34.4 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$34.4 million, -$18.1 million, and -$42.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.